2023
A large-scale retrospective study enabled deep-learning based pathological assessment of frozen procurement kidney biopsies to predict graft loss and guide organ utilization
Yi Z, Xi C, Menon M, Cravedi P, Tedla F, Soto A, Sun Z, Liu K, Zhang J, Wei C, Chen M, Wang W, Veremis B, Garcia-Barros M, Kumar A, Haakinson D, Brody R, Azeloglu E, Gallon L, O'Connell P, Naesens M, Shapiro R, Colvin R, Ward S, Salem F, Zhang W. A large-scale retrospective study enabled deep-learning based pathological assessment of frozen procurement kidney biopsies to predict graft loss and guide organ utilization. Kidney International 2023, 105: 281-292. PMID: 37923131, PMCID: PMC10892475, DOI: 10.1016/j.kint.2023.09.031.Peer-Reviewed Original ResearchArterial intimal fibrosisGraft lossOrgan utilizationIntimal fibrosisSclerotic glomeruliLarge-scale retrospective studyGlomerular filtration rateDeceased donor kidneysPathologist scoresTransplant outcomesBiopsy findingsSurvival prediction modelWedge biopsyRisk stratificationRetrospective studyFiltration ratePathological assessmentDonor biopsiesNeedle biopsySimilar survivalHistological scoringUnnecessary organsDiscovery setKidneyLesion scores
2022
Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS)
Brunner A, Gavralidis A, Ali N, Hunter A, Komrokji R, Zeidan A, Sallman D. Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS). Blood Cancer Journal 2022, 12: 153. PMID: 36379923, PMCID: PMC9666661, DOI: 10.1038/s41408-022-00748-9.Peer-Reviewed Original ResearchConceptsPartial hematologic recoveryMyelodysplastic syndromeHematologic recoveryResponse criteriaCR/CRhIWG 2006 criteriaDuration of therapyBest overall responseTime of therapyCR responseCRH responseDNMTi therapyOS associationComplete remissionMedian OSOverall survivalAdult patientsAllogeneic transplantsMedian ageMDS patientsMultivariable analysisClinical trialsSimilar survivalPatientsTherapy
2020
Equivalent Survival Between Lobectomy and Segmentectomy for Clinical Stage IA Lung Cancer
Onaitis MW, Furnary AP, Kosinski AS, Feng L, Boffa D, Tong BC, Cowper P, Jacobs JP, Wright CD, Habib R, Putnam JB, Fernandez FG. Equivalent Survival Between Lobectomy and Segmentectomy for Clinical Stage IA Lung Cancer. The Annals Of Thoracic Surgery 2020, 110: 1882-1891. PMID: 32119855, DOI: 10.1016/j.athoracsur.2020.01.020.Peer-Reviewed Original ResearchConceptsThoracic Surgeons databaseSurgeons databaseLung cancerSimilar survivalClinical stage IA lung cancerClinical stage IA diseaseStage IA lung cancerEarly-stage lung cancerPositron emission tomography resultsThoracic Surgeons General Thoracic Surgery DatabaseStage IA diseaseGeneral Thoracic Surgery DatabaseLung cancer patientsMediastinal staging proceduresThoracic Surgery DatabaseLong-term survivalIA diseaseN0 patientsStaging procedureOncologic efficacyCox regressionEntire cohortCancer patientsClinical variablesEquivalent survivalEffect of Time to Surgery of Colorectal Liver Metastases on Survival
Chen EY, Mayo SC, Sutton T, Kearney MR, Kardosh A, Vaccaro GM, Billingsley KG, Lopez CD. Effect of Time to Surgery of Colorectal Liver Metastases on Survival. Journal Of Gastrointestinal Cancer 2020, 52: 169-176. PMID: 32086781, PMCID: PMC7900034, DOI: 10.1007/s12029-020-00372-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantColorectal NeoplasmsDisease-Free SurvivalFemaleFollow-Up StudiesHepatectomyHumansKaplan-Meier EstimateLiver NeoplasmsMaleMiddle AgedNeoadjuvant TherapyNeoplasm Recurrence, LocalPrognosisRetrospective StudiesTime FactorsTime-to-TreatmentYoung AdultConceptsColorectal liver metastasesLong-term OSPostoperative overall survivalOverall survivalLonger TTSLiver metastasesWorse survivalDiagnosis of CLMLong-term survivorsResultsTwo hundred eightyRisk of recurrenceComprehensive cancer centerHigh disease burdenSpecific primary tumorsShorter TTSPerioperative chemotherapyPostoperative chemotherapyPerioperative treatmentResection marginsCancer CenterMetastasis characteristicsInstitutional databasePrimary tumorDisease burdenSimilar survival
2019
Outcomes After Listing for Liver Transplant in Patients With Acute‐on‐Chronic Liver Failure: The Multicenter North American Consortium for the Study of End‐Stage Liver Disease Experience
O’Leary J, Bajaj JS, Tandon P, Biggins SW, Wong F, Kamath PS, Garcia‐Tsao G, Maliakkal B, Lai J, Fallon M, Vargas HE, Thuluvath P, Subramanian R, Thacker LR, Reddy K. Outcomes After Listing for Liver Transplant in Patients With Acute‐on‐Chronic Liver Failure: The Multicenter North American Consortium for the Study of End‐Stage Liver Disease Experience. Liver Transplantation 2019, 25: 571-579. PMID: 30724010, PMCID: PMC11075742, DOI: 10.1002/lt.25426.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryAcute-On-Chronic Liver FailureAdultDisease ProgressionEnd Stage Liver DiseaseFemaleHospital MortalityHospitalizationHumansLiver CirrhosisLiver TransplantationMaleMiddle AgedNorth AmericaProspective StudiesRenal DialysisSeverity of Illness IndexSurvival RateTime-to-TreatmentWaiting ListsConceptsChronic liver failureLiver transplantationNorth American ConsortiumLiver failureEnd-stage liver disease (MELD) scoreEnd-stage liver diseaseAmerican ConsortiumExtrahepatic organ failureAcute kidney injuryLiver Disease scoreOutcomes of patientsPost-LT survivalPerioperative dialysisRenal recoveryKidney injuryLiver transplantOrgan failureLiver diseaseMedian timeMedian MELDACLFSimilar survivalDisease experienceDisease scorePatients
2018
Whole Versus Partial Bladder Radiation
Kang J, Steinberg M, Kupelian P, Alexander S, King C. Whole Versus Partial Bladder Radiation. American Journal Of Clinical Oncology 2018, 41: 107-114. PMID: 26535994, DOI: 10.1097/coc.0000000000000237.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCarcinoma, Transitional CellCohort StudiesDisease-Free SurvivalFemaleGeriatric AssessmentHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm InvasivenessNeoplasm StagingOrgan Sparing TreatmentsPrognosisRadiation Dose HypofractionationRadiation InjuriesRadiotherapy, Image-GuidedRadiotherapy, Intensity-ModulatedRetrospective StudiesRisk AssessmentSurvival AnalysisTreatment OutcomeUnited StatesUrinary Bladder NeoplasmsConceptsOverall survivalLymph nodesWhole bladderLocal controlMuscle-invasive bladder cancerMuscle-invasive recurrenceMulti-institutional cohortSimultaneous integrated boostIntensity-modulated radiation therapyDefinitive chemoradiationPrimary endpointSecondary endpointsBladder treatmentLocal recurrenceUrothelial cancerMean ageBladder cancerIntegrated boostInstitutional experienceRetrospective analysisBladder wallBoost volumeRadiation therapySimilar survivalTherapeutic ratio
2016
At the Root of the Repair Debate: Outcomes After Elective Aortic Root Replacements for Aortic Insufficiency With Aneurysm
McCarthy FH, Bavaria JE, McDermott KM, Moeller P, Spragan D, Hoedt A, Dibble T, Savino D, Williams ML, Vallabhajosyula P, Szeto WY, Desai ND. At the Root of the Repair Debate: Outcomes After Elective Aortic Root Replacements for Aortic Insufficiency With Aneurysm. The Annals Of Thoracic Surgery 2016, 102: 1199-1205. PMID: 27261085, DOI: 10.1016/j.athoracsur.2016.03.071.Peer-Reviewed Original ResearchMeSH KeywordsAdultAortic Aneurysm, ThoracicAortic Valve InsufficiencyBlood Vessel Prosthesis ImplantationCause of DeathDatabases, FactualElective Surgical ProceduresFemaleFollow-Up StudiesHeart Valve Prosthesis ImplantationHospital MortalityHumansKaplan-Meier EstimateMaleMiddle AgedPostoperative ComplicationsRetrospective StudiesRisk AssessmentSurvival AnalysisTreatment OutcomeConceptsModerate aortic insufficiencySevere aortic insufficiencyAortic insufficiencyLong-term survivalRoot replacementWorse survivalAI patientsDecreased long-term survivalElective aortic root replacementWorse long-term survivalPreoperative aortic insufficiencyPreoperative renal failureAortic root replacementAppropriate therapeutic strategiesGreater aortic insufficiencyTiming of interventionUnited States populationRenal failureYounger patientsMultivariable predictorsSimilar patientsAortic aneurysmSingle institutionInclusion criteriaSimilar survivalCorrelation of body mass index with female survival benefit among a single-institution cohort of cutaneous melanomas >1 mm thick following wide-local excision and sentinel lymph node biopsy.
Jackson L, Bulloch K, Narayan D, Ariyan S, Gould Rothberg BE. Correlation of body mass index with female survival benefit among a single-institution cohort of cutaneous melanomas >1 mm thick following wide-local excision and sentinel lymph node biopsy. Journal Of Clinical Oncology 2016, 34: 172-172. DOI: 10.1200/jco.2016.34.3_suppl.172.Peer-Reviewed Original ResearchBody mass indexDisease-free survivalWide local excisionCutaneous melanomaSurvival benefitSentinel lymphMass indexNormal-weight menNormal-weight womenSingle-institution cohortCox proportional hazardsNon-therapeutic interventionsFree survivalSLN statusWeight womenClinicopathologic factorsConsecutive patientsLocal excisionMultivariable analysisWeight menLifestyle factorsActive surveillanceSimilar survivalSurvival advantageMitotic count
2014
The Incidence, Risk, and Consequences of Atrial Arrhythmias in Patients with Continuous‐Flow Left Ventricular Assist Devices
Brisco MA, Sundareswaran KS, Milano CA, Feldman D, Testani JM, Ewald GA, Slaughter MS, Farrar DJ, Goldberg LR, Investigators F. The Incidence, Risk, and Consequences of Atrial Arrhythmias in Patients with Continuous‐Flow Left Ventricular Assist Devices. Journal Of Cardiac Surgery 2014, 29: 572-580. PMID: 24750460, DOI: 10.1111/jocs.12336.Peer-Reviewed Original ResearchConceptsLeft ventricular assist deviceLate atrial arrhythmiaAtrial arrhythmiasVentricular assist deviceFunctional statusRisk factorsAssist deviceHeartMate II Left Ventricular Assist DeviceIncidence of AASix-minute walk distanceDestination therapy trialsDays of supportStrong risk factorQuality of lifePreoperative creatinineLVAD patientsSerum creatinineWalk distanceEjection fractionHeart failureLVAD supportQOL improvementMultivariable modelSimilar survivalBlanking period
2002
Race, Treatment, and Survival of Veterans With Cancer of the Distal Esophagus and Gastric Cardia
Dominitz J, Maynard C, Billingsley K, Boyko E. Race, Treatment, and Survival of Veterans With Cancer of the Distal Esophagus and Gastric Cardia. Medical Care 2002, 40: i-14. PMID: 11789626, DOI: 10.1097/00005650-200201001-00003.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaBlack or African AmericanCarcinoma, Squamous CellCardiaChemotherapy, AdjuvantCohort StudiesEsophageal NeoplasmsEsophagectomyEsophagogastric JunctionHealth Services AccessibilityHealth Services ResearchHospitals, VeteransHumansMaleProportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesSurvival AnalysisUnited StatesVeteransWhite PeopleConceptsSquamous cell carcinomaDistal esophageal cancerSurgical resectionBlack patientsRadiation therapyEsophageal cancerEsophageal adenocarcinomaEqual‐access medical systemWhite veteransVeterans Affairs Medical CenterBlack male veteransDistal esophageal adenocarcinomaSurvival of veteransRetrospective cohort studySurvival of patientsCohort studyGastric cardiaDistal esophagusSimilar oddsCell carcinomaCancer survivalMedical CenterInvasive proceduresLower oddsSimilar survival
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply